Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine
-
By
-
Elif Ilgaz Aydınlar
-
Pınar Yalınay Dikmen
-
Aysenur Sahin
-
Kerem Birısık
-
June 1, 2026
-
Clinical Scorecard: Improvement in Photophobia Symptoms with Galcanezumab Treatment in Patients with Episodic and Chronic Migraine
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | CGRP monoclonal antibody targeting (source needed) |
| Target Population | Patients aged 18–65 years with episodic and chronic migraine (source needed) |
| Care Setting | |
Key Highlights
- Remove unsupported conclusions about treatment implications.
Guideline-Based Recommendations
Diagnosis
Management
- G
- a
- l
- c
- a
- n
- e
- z
- u
- m
- a
- b
-
- a
- d
- m
- i
- n
- i
- s
- t
- e
- r
- e
- d
-
- a
- s
-
- a
-
- 2
- 4
- 0
-
- m
- g
-
- l
- o
- a
- d
- i
- n
- g
-
- d
- o
- s
- e
-
- f
- o
- l
- l
- o
- w
- e
- d
-
- b
- y
-
- m
- o
- n
- t
- h
- l
- y
-
- 1
- 2
- 0
-
- m
- g
-
- (
- s
- o
- u
- r
- c
- e
-
- n
- e
- e
- d
- e
- d
- )
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Galcanezumab associated with improvements in headache frequency, severity, disability, and psychological comorbidities (source needed)
Clinical Best Practices
- Ensure practices are directly supported by the source material.
Related Resources & Content
